Amifampridine - BioMarin

Drug Profile

Amifampridine - BioMarin

Alternative Names: 3,4-DAP; 3,4-DAP phosphate; 3,4-Diaminopyridine; Amifampridine phosphate; Firdapse; Pyridine-3,4-diamine-monophosphate; Zenas

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Assistance Publique Hopitaux de Paris
  • Developer BioMarin Pharmaceutical; Catalyst Pharmaceuticals; Fondazione Istituto Neurologico Carlo Besta
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lambert-Eaton myasthenic syndrome; Myasthenia gravis; Congenital myasthenic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lambert-Eaton myasthenic syndrome
  • Phase III Congenital myasthenic syndromes; Myasthenia gravis
  • Phase II Spinal muscular atrophy

Most Recent Events

  • 01 Jul 2018 Catalyst Pharmaceuticals initiates enrolment in a phase III trial for Myasthenia Gravis in USA (NCT03579966)
  • 29 May 2018 The US FDA sets PDUFA date of 28/11/2018 for NDA review for amifampridine
  • 29 May 2018 Amifampridine receives priority review status for Lambert-Eaton Myasthenic Syndrome (LEMS) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top